Related Experiment Videos
[Coagulation disorders in tumors and hemoblastoses]
Onkologie
|August 1, 1982
Summary
Malignant diseases cause coagulation disorders, leading to thrombosis and bleeding. Solid tumors show hypercoagulability and hypofibrinolysis, while leukemias often involve thrombocytopenia and fibrinolysis.
Area of Science:
- Hematology
- Oncology
- Clinical Pathology
Context:
- Thromboembolic and hemorrhagic complications frequently occur in patients with malignant diseases.
- Understanding the underlying coagulation disorders is crucial for managing these complications.
Purpose:
- To investigate and characterize the coagulation disorders associated with solid tumors and leukemias.
- To identify the specific hemostatic abnormalities contributing to thrombotic and bleeding risks in cancer patients.
Summary:
- Coagulation analysis revealed hypercoagulability (shortened partial thromboplastin time and increased factor VIII activity) in both solid tumor and leukemia patients.
- Solid tumors exhibited elevated fibrinogen, hypofibrinolysis (prolonged euglobulin lysis time), and increased platelet aggregation.
- Leukemia-associated bleeding complications were primarily linked to thrombocytopenia, but also potentially to activated fibrinolysis or reduced factor XIII, indicating clot instability.
Impact:
- This research elucidates the complex prothrombotic and hemorrhagic diatheses in cancer.
- Findings contribute to a better understanding of tumor-induced coagulation abnormalities, potentially guiding therapeutic strategies.
- Highlights the distinct hemostatic profiles in solid tumors versus leukemias, informing differential diagnosis and management.